Baxter

Baxter International, Inc. engages in the provision of a portfolio of essential renal and hospital products, including acute and chronic dialysis, sterile IV solutions, infusion systems and devices, parenteral nutrition therapies, premixed and oncolytic injectable, bio surgery products and anesthetics, drug reconstitution systems and pharmacy automation, software, and services. It operates through the following segment: Americas, Europe, Middle East and Africa (EMEA), Asia-Pacific (APAC), and Hillrom. The Americas, EMEA, and APAC segments offer a portfolio of essential healthcare products. The Hillrom segment provides digital and connected care solutions and collaboration tools, including smart bed systems, patient monitoring and diagnostic technologies, respiratory health devices and advanced equipment for the surgical space. The company was founded by Davis Baxter in 1931 and is headquartered in Deerfield, IL.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Baxter reports robust Q4 sales, eyes growth amid operational challenges

Baxter International's Q4 2022 performance reflects strong sales growth and strategic actions to enhance agility and market responsiveness.
While facing challenges such as lower-than-expected earnings and supply chain constraints, the company is focused on cost reduction and operational improvements.
Opportunities lie in R&D investments, cost synergies from the Hillrom integration, and improving backlog and backorders, positioning Baxter for future growth.
Analysts' concerns about operating margins and financial outlook for 2023 highlight the need for continued efficiency measures and strategic planning.

Baxter beats Q1 expectations, plans spin-off for strategic clarity

Baxter's Q1 performance exceeded expectations with sales growth in key segments and adjusted EPS surpassing guidance.
The company is progressing well with its strategic initiatives, including the spin-off of Renal Care and new operating model.
Challenges in legacy businesses and soft hospital spending highlight areas for improvement, while opportunities lie in new product launches and margin enhancement strategies.
Overall, Baxter's focus on innovation, operational efficiency, and market trends positions it for long-term success and growth.

Baxter exceeds Q2 expectations, eyes growth amid strategic actions

Baxter's Q2 2023 performance showcased resilience and adaptability in a dynamic healthcare market, with strategic actions underway to drive operational efficiency and growth.
The company's focus on innovation, safety, and market responsiveness positions it well for future success, despite challenges such as pending divestitures and market uncertainties.
With a strong performance, growth opportunities in key segments, and operational improvements driving margin expansion, Baxter is navigating challenges to capitalize on future growth prospects.

Baxter beats Q3 expectations, eyes growth through strategic initiatives

Baxter's Q3 2023 performance exceeded expectations, with a focus on strategic priorities and the upcoming Kidney Care segment separation.
The company's strengths lie in maintaining market share, operational efficiencies, and maximizing shareholder value through financial analysis.
Challenges include renegotiating contracts, rising energy costs, and achieving organic growth amidst market dynamics.
Opportunities for Baxter include growth through cost improvements, margin programs, and product launches in 2024.

Baxter surpasses Q4 expectations, eyes growth amid inflation challenges

Baxter's Q4 2023 performance exceeded expectations, driven by growth in key segments and strategic initiatives, setting the stage for continued success in 2024.
Despite challenges like inflation and flat growth in certain segments, Baxter's focus on margin improvement, debt management, and growth strategies positions the company for future resilience.
With a strong outlook for 2024, Baxter aims to capitalize on opportunities for growth, margin improvement, and market expansion, supported by a solid financial foundation and strategic priorities.

Baxter surpasses Q1 expectations with focus on innovation and growth

Baxter's Q1 2024 performance exceeded expectations, driven by strong sales growth and focus on innovation, despite challenges in certain segments and geographies.
The company's strategic strengths lie in diverse growth drivers, strong segment margins, and geographic expansion successes, positioning it for continued success.
Addressing challenges in underperforming segments and markets, along with seizing opportunities for improvement and expansion, will be crucial for Baxter's future growth.
With a clear focus on innovation, margin expansion, and shareholder value maximization, Baxter aims to navigate challenges and capitalize on growth prospects for sustained success.

Baxter exceeds Q2 expectations, plans Kidney Care separation for growth

Baxter International's Q2 2024 earnings call highlighted robust performance, strategic initiatives, and a positive outlook for sales growth and earnings per share.
The company's focus on margin improvement, innovation, and operational efficiency positions it well for sustained growth and shareholder value creation.
While facing challenges in certain segments and external factors, Baxter's proactive approach and strong fundamentals offer opportunities for future expansion and success.
Investors can look forward to Baxter's continued commitment to driving growth, expanding margins, and delivering innovative healthcare solutions.

Baxter reports solid Q3 performance amidst challenges and growth opportunities

Baxter International demonstrated resilience in Q3 2024 with sales growth and earnings exceeding expectations despite challenges.
The company's focus on operational efficiency, cost containment, and strategic divestitures positions it well for future growth.
Challenges from Hurricane Helene impact and Kidney Care separation are being addressed with a clear vision for sustained performance.
Opportunities for growth and margin expansion underscore Baxter's commitment to delivering value to shareholders and patients.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Baxter International, Inc. engages in the provision of a portfolio of essential healthcare products including acute and chronic dialysis therapies, sterile intravenous (IV) solutions, infusion systems and devices, parenteral nutrition therapies, inhaled anesthetics, generic injectable pharmaceuticals, surgical hemostat and sealant products, surgical equipment, smart bed systems, patient monitoring and diagnostic technologies, and respiratory health devices. It operates through the following segments: Americas, Europe, Middle East and Africa (EMEA), Asia-Pacific (APAC), and Hillrom. The Americas, EMEA, and APAC segments offer a portfolio of essential healthcare products. The Hillrom segment provides digital and connected care solutions and collaboration tools, including smart bed systems, patient monitoring and diagnostic technologies, respiratory health devices, and equipment for the surgical space. The company was founded by Davis Baxter in 1931 and is headquartered in Deerfield, IL.

Baxter's (BAX) second-quarter results reflect robust performance across all its business units.

Baxter (BAX) Q2 Earnings Surpass Estimates, Revenues Miss

Baxter (BAX) delivered earnings and revenue surprises of 8.11% and -0.47%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Baxter International (BAX) Q2 Earnings Surpass Estimates

Baxter International Inc (NYSE: BAX) Q2 revenue of $3.1 billion, in line with the consensus, increased 14% on a reported basis, 9% on a constant currency basis, and 8% on an operational basis. Adjusted EPS of $0.80 increased 25% and surpassed the estimate of $0.75.

Baxter Q2 Earnings Marginally Beat Estimates; Revises Upper End Of 2021 EPS Outlook

CryoLife

ATLANTA, July 29, 2021 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a leading cardiac and vascular surgery company focused on aortic disease, announced today that it has completed the sale of its PerClot product line to a subsidiary of Baxter International, Inc. ("Baxter") (NYSE: BAX ), for up to $60.8 million in cash. Of the $60.8 million, CryoLife will receive up to $45.8 million and Starch Medical, Inc. ("SMI") will receive up to $15.0 million.

CryoLife Announces Sale of PerClot to Baxter

DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a leading global medical products company, announced its Baxter Healthcare Corporation subsidiary has completed the acquisition of certain assets related to PerClot Polysaccharide Hemostatic System from CryoLife, Inc (NYSE:CRY) for up to $60.8 million, including $25 million paid upfront. The remainder will be paid out upon achievement of certain select milestones. The transaction reinforces Baxter's strategy of acquiring pr

Baxter Announces Acquisition of PerClot Polysaccharide Hemostatic System to Expand Advanced Surgery Portfolio

DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a leading global medical products company, today reported results for the second quarter of 2021. “As markets worldwide continue to cope with the effects from the COVID-19 pandemic, Baxter's second quarter performance reflects the diversity and durability of our lifesaving portfolio combined with the breadth of our geographic reach,” said José (Joe) E. Almeida, chairman, president and chief executive officer. “Our drive to

Baxter Reports Second-Quarter 2021 Results

Baxter (BAX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Why the Earnings Surprise Streak Could Continue for Baxter (BAX)

According to people familiar with the matter, Baxter International Inc (NYSE: BAX) is reportedly in talks to buy Hill-Rom Holdings Inc (NYSE: HRC). The talks are at an early stage, some of the people said, and there's no guarantee a deal will be reached.

Hill Rom Stock Shoots Higher As Baxter In Early Talks To Acquire Company: WSJ

Baxter's (BAX) second-quarter results are likely to reflect growth in its Acute Therapies business.

Baxter (BAX) to Report Q2 Earnings: What's in the Cards?

AbbVie

Bristol-Myers

Cigna

Cisco Systems

Chevron

D.R. Horton

Gaming and Leisure Properties

Barrick Gold

Intel

Johnson & Johnson

Lowe's

Merck

PepsiCo

Raytheon Technologies

Exxon Mobil

Kiplinger Investing publishes opportune buy-lists for investors online. Two billionaire stock-lists by Dan Burrows included 50 published 12/8/20, with 30 more out June 1, 2021. Seventeen were duplicated, leaving 63. 41 of these 63 billionaire-held stocks pay dividends. As of 7/20/21, the top-ten ranged 2.52%-6.22% by annual yield and ranged 23.13%-52.70% per broker-estimated price-target upsides.

Pre-August Billionaire Flash: 63 Stocks, 41 Dividends, 3 Buys

DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a global leader in advancing surgical innovation, recognizes the findings of a large retrospective observational analysis published in the Journal of Medical Economics. The Baxter-sponsored analysis demonstrated that the use of active hemostatic products alone was associated with lower rates of bleeding-related complications, shorter hospital stays and reduced total hospital costs compared to combined use of passive and act

Baxter Supports Analysis Demonstrating Clinical and Economic Benefits of Effective Intraoperative Blood Management for Surgical Patients

Conagra Brands

Duke Energy

Fastenal

The Company's new quarterly dividend payment of $0.3125 per share of Conagra common stock will be paid on September 2, 2021 to stockholders of record as of the close of business on August 3, 2021.

Daily Dividend Report: Conagra Brands, Fastenal, Baxter International, AON, Duke Energy

DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a leading global medical products company, today released its 2020 Corporate Responsibility Report. This year's report details final achievement towards Baxter's 2015-2020 set of corporate responsibility priorities and goals and launches the company's new 2030 corporate responsibility commitment to advance environmental, social and governance (ESG) performance over the next decade. “The global challenges presented in 2020 i

Baxter Launches New 2030 Corporate Responsibility Commitment to Advance Environmental, Social and Governance Priorities

BellRing Brands Inc

Maravai LifeSciences Holdings

Here are three stocks, BAX, BRBR, and MRVI with a favorable Zacks Rank and huge prospects in child healthcare at present.

Child Health in Focus in Face of Delta Strain Threat: 3 Picks

DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter Announces $1.2 Million in Funding to Support Students Pursuing Health and Sciences Degrees at HBCUs w/Activating Change Today (ACT) Initiative

Baxter Announces $1.2 Million in New Scholarships and Grant Funding to Support Students Pursuing Health and Sciences at Historically Black Colleges and Universities in the United States

NEWTON, Mass.--(BUSINESS WIRE)--Hospital IQ, the leading provider of predictive hospital operations and communications software, secured $25 million in Series C funding led by Baxter Ventures, the venture investment arm of Baxter International Inc. (NYSE: BAX), and Health Velocity Capital, joining existing investors Pierpoint Capital and Allscripts. The investment comes amid a year of unprecedented company growth as its AI-enabled operations management platform solved operational inefficiencies

Hospital IQ Raises $25 Million to Meet Market Demand for its Software which Optimizes Health System Operations

DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a leading global medical products company, will host a conference call to discuss its second-quarter 2021 financial results on Thursday, July 29, 2021 at 7:30 a.m. Central Time. To participate in this conference call please follow this link http://www.directeventreg.com/registration/event/8371319 to pre-register for the call and receive the call information. This call is also being webcast and can be accessed through Baxter

Baxter to Host Second-Quarter 2021 Financial Results Conference Call for Investors

Baxter's (BAX) Theranova-enabled HDx therapy is likely to boost clinical outcomes and lower healthcare resource utilization.

Baxter's (BAX) Theranova-Enabled HDx Therapy Data Positive

DEERFIELD, Ill.--(BUSINESS WIRE)-- #HDx--Baxter International Inc. (NYSE:BAX), a global innovator in renal care, announced today new data showing expanded hemodialysis (HDx) therapy enabled by the Theranova dialyzer may reduce cardiovascular events by 35% and hospitalization rates by 18% according to a new, large, multicenter, retrospective study of Colombian dialysis patients treated with long-term HDx compared to propensity-matched patients treated with High-Flux Hemodialysis.1 The study “Effectiven

Baxter Presents Data at 58th ERA-EDTA Congress Indicating Theranova May Reduce Cardiovascular Events and Hospitalizations

Baxter (BAX) introduces new clinical management resource within the Sharesource remote patient management platform for home dialysis patients.

Baxter (BAX) Unveils New Digital Health Module for PD Patients

DEERFIELD, Ill.--(BUSINESS WIRE)-- #DigitalHealth--Baxter International Inc. (NYSE:BAX), a global innovator in renal care, announced today the launch of the Sharesource Analytics 1.0 premium module, the next generation of digital health for home-based peritoneal dialysis (PD) patients. Sharesource Analytics 1.0 is a clinical management resource within the Sharesource remote patient management platform that provides healthcare professionals with a comprehensive dashboard containing simplified trend data from the

Baxter Launches the Sharesource Analytics 1.0 Digital Health Module to Enhance Clinical Management of Home Dialysis Patients

Baxter's (BAX) PrisMax 2 aims to enhance user experience and help in addressing the unique demands of the ICU.

Baxter's (BAX) PrisMax 2 to Simplify Organ Support Therapies

DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a global leader in acute care, today announced the global launch of PrisMax 2, the latest version of the company's next-generation platform. PrisMax 2 is designed to help simplify delivery of continuous renal replacement therapy (CRRT) and other organ support therapies, while providing hospitals the flexibility to meet the unique demands of the intensive care unit (ICU). The PrisMax 2 system features new solutions within th

Baxter Launches PrisMax 2 System to Advance Critical Care Delivery for Patients and Hospitals

DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a leading global medical products company, will present at the UBS Global Healthcare Virtual Conference on Tuesday, May 25, 2021. Jay Saccaro, Baxter's chief financial officer, is scheduled to present at 2:00 p.m. Eastern Time. The live webcast of Baxter's presentation can be accessed at www.baxter.com and will be available for replay through June 24, 2021. About Baxter Every day, millions of patients and caregivers rely on

Baxter to Present at the UBS Global Healthcare Virtual Conference

Baxter International Inc.'s (BAX) CEO Joe Almeida on Q1 2021 Results - Earnings Call Transcript

News for Baxter Stock (BAX)